BPG is committed to discovery and dissemination of knowledge
Articles in Press
12/11/2025 7:14:53 AM | Browse: 24 | Download: 0
Publication Name World Journal of Diabetes
Manuscript ID 112867
Country China
Category Endocrinology & Metabolism
Manuscript Type Retrospective Study
Article Title Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy
Manuscript Source Unsolicited Manuscript
All Author List Yan Miao, Pan He, Dan-Yu Wang, Lei Yan, Hui-Xia Cao and Feng-Min Shao
Funding Agency and Grant Number
Funding Agency Grant Number
Major Public Welfare Projects in Henan Province 201300310700
Health Commission Project of Henan Province SBGJ202301001
Corresponding Author Feng-Min Shao, Department of Nephrology, People's Hospital of Zhengzhou University and Henan Provincial People's Hospital, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, No. 7 Weiwu Road, Jinshui District, Zhengzhou 450003, Henan Province, China. shaofengmin123@163.com
Key Words Diabetic nephropathy; Semaglutide; Canagliflozin; Combination therapy; Glucose-lipid metabolism; Renoprotection
Core Tip This retrospective study demonstrates that, in individuals with type 2 diabetes and nephropathy, the addition of semaglutide to canagliflozin monotherapy provides better renal protection and metabolic improvements compared to canagliflozin alone. The combination significantly reduced proteinuria, improved glycemic and lipid control, enhanced β-cell function, alleviated systemic inflammation and oxidative stress, without increasing adverse events. It offers an effective and safe intensification therapy option, particularly for those who have not achieved optimal levels of proteinuria or metabolic parameters under sodium-glucose cotransporter-2 inhibitor monotherapy.
Citation Miao Y, He P, Wang DY, Yan L, Cao HX, Shao FM. Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy. World J Diabetes 2025; In press
Received
2025-08-26 09:23
Peer-Review Started
2025-08-27 00:45
First Decision by Editorial Office Director
2025-10-13 07:23
Return for Revision
2025-10-13 07:23
Revised
2025-10-28 08:42
Publication Fee Transferred
2025-11-03 07:58
Second Decision by Editor
2025-12-01 11:23
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2025-12-11 07:14
Articles in Press
2025-12-11 07:14
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-9358 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com